Business Context and Reporting Period
This Form 8-K is a current report filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on May 9, 2019. The filing announces the Company's financial results for the first quarter of 2019. The Company is incorporated in Delaware and its common stock trades on the NASDAQ Global Market under the symbol ZFGN.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It serves primarily as a notification that Q1 2019 results have been announced and directs investors to the attached press release for comparative data.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference in any other filing, except as expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the specific Q1 2019 financial figures (revenue, net loss, cash position) in Exhibit 99.1 (the press release).
- Confirm the Company name is Zafgen, Inc. (ZFGN), as the input metadata incorrectly referenced Larimar Therapeutics, Inc.
- Review the press release for any updates on clinical trials or product development, as this is a biopharmaceutical company.
- Check for any forward-looking statements or revised guidance included in the attached press release.